281 related articles for article (PubMed ID: 31493740)
1. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW
Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740
[TBL] [Abstract][Full Text] [Related]
2. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
Saxena AK; Saxena S; Chaudhaery SS
SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
[TBL] [Abstract][Full Text] [Related]
4. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
5. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors.
Saxena S; Chaudhaery SS; Varshney K; Saxena AK
SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581
[TBL] [Abstract][Full Text] [Related]
7. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
[TBL] [Abstract][Full Text] [Related]
8. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
Khandelwal A; Crowley VM; Blagg BSJ
Med Res Rev; 2016 Jan; 36(1):92-118. PubMed ID: 26010985
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of Antiangiogenic Potential of Vitexin Obtained from Cucumis sativus Targeting Hsp90 Protein: A Novel Multipathway Targeted Approach to Restrain Angiogenic Phenomena.
Sharma N; Akhtar S; Jamal QMS; Kamal MA; Khan MKA; Siddiqui MH; Sayeed U
Med Chem; 2017; 13(3):282-291. PubMed ID: 27834134
[TBL] [Abstract][Full Text] [Related]
10. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
[TBL] [Abstract][Full Text] [Related]
11. Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review.
Zarguan I; Ghoul S; Belayachi L; Benjouad A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791506
[TBL] [Abstract][Full Text] [Related]
12. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
[TBL] [Abstract][Full Text] [Related]
13. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
Franke J; Eichner S; Zeilinger C; Kirschning A
Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Studies.
AbdElmoniem N; H Abdallah M; M Mukhtar R; Moutasim F; Rafie Ahmed A; Edris A; Ibraheem W; Makki AA; M Elshamly E; Elhag R; Osman W; A Mothana R; Alzain AA
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838758
[TBL] [Abstract][Full Text] [Related]
15. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer.
Neckers L
Curr Top Med Chem; 2006; 6(11):1163-71. PubMed ID: 16842153
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
[TBL] [Abstract][Full Text] [Related]
17. Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target.
Dunna NR; Bandaru S; Akare UR; Rajadhyax S; Gutlapalli VR; Yadav M; Nayarisseri A
Curr Top Med Chem; 2015; 15(1):57-64. PubMed ID: 25579569
[TBL] [Abstract][Full Text] [Related]
18. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
[TBL] [Abstract][Full Text] [Related]
19. In silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent.
Gupta UK; Mahanta S; Paul S
Med Hypotheses; 2013 Nov; 81(5):853-61. PubMed ID: 24018284
[TBL] [Abstract][Full Text] [Related]
20. Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents.
Kim HS; Hoang VH; Hong M; Chul Kim K; Ann J; Nguyen CT; Seo JH; Choi H; Yong Kim J; Kim KW; Sub Byun W; Lee S; Lee S; Suh YG; Chen J; Park HJ; Cho TM; Kim JY; Seo JH; Lee J
Bioorg Med Chem; 2019 Apr; 27(7):1370-1381. PubMed ID: 30827868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
